Total Payments
$2.2M
2024 Payments
$253,081
Companies
59
Transactions
4,373
Medicare Patients
5,465
Medicare Billing
$6.5M
Payment Breakdown by Category
Other$1.6M (71.6%)
Travel$338,460 (15.4%)
Consulting$209,657 (9.6%)
Food & Beverage$73,949 (3.4%)
Research$951.58 (0.0%)
Education$439.54 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.5M | 673 | 70.4% |
| Travel and Lodging | $338,460 | 878 | 15.4% |
| Consulting Fee | $209,657 | 83 | 9.6% |
| Food and Beverage | $73,949 | 2,699 | 3.4% |
| Honoraria | $25,857 | 13 | 1.2% |
| Unspecified | $951.58 | 6 | 0.0% |
| Education | $439.54 | 21 | 0.0% |
Payments by Type
General
$2.2M
4,367 transactions
Research
$951.58
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $486,610 | 449 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $307,929 | 309 | $0 (2024) |
| Lilly USA, LLC | $240,891 | 463 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $197,866 | 365 | $0 (2024) |
| Amgen Inc. | $181,860 | 339 | $0 (2024) |
| UCB, Inc. | $169,618 | 397 | $0 (2024) |
| Genentech USA, Inc. | $144,110 | 184 | $0 (2024) |
| ABBVIE INC. | $118,429 | 342 | $0 (2024) |
| GlaxoSmithKline, LLC. | $101,965 | 186 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $75,258 | 129 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $253,081 | 568 | AstraZeneca Pharmaceuticals LP ($129,864) |
| 2023 | $231,453 | 532 | AstraZeneca Pharmaceuticals LP ($101,446) |
| 2022 | $198,293 | 533 | UCB, Inc. ($46,673) |
| 2021 | $227,729 | 449 | AstraZeneca Pharmaceuticals LP ($52,277) |
| 2020 | $141,593 | 331 | Amgen Inc. ($53,052) |
| 2019 | $407,096 | 707 | Celgene Corporation ($115,074) |
| 2018 | $390,625 | 681 | Celgene Corporation ($143,841) |
| 2017 | $344,567 | 572 | Celgene Corporation ($223,119) |
All Payment Transactions
4,373 individual payment records from CMS Open Payments — Page 1 of 175
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/19/2024 | UCB, Inc. | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $6,900.00 | General |
| Category: Immunology | ||||||
| 12/19/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $98.00 | General |
| Category: Immunology | ||||||
| 12/19/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $48.37 | General |
| Category: Immunology | ||||||
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $13.83 | General |
| Category: Immunology | ||||||
| 12/19/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $6.88 | General |
| Category: Inflammation | ||||||
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $1.56 | General |
| Category: Immunology | ||||||
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $0.30 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $19.14 | General |
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $47.37 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $3.39 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/17/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $2.57 | General |
| Category: Dermatology | ||||||
| 12/16/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | In-kind items and services | $1,563.30 | General |
| Category: Inflammation | ||||||
| 12/16/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/16/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $13.99 | General |
| Category: Inflammation | ||||||
| 12/13/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,330.00 | General |
| Category: Inflammation | ||||||
| 12/13/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $555.00 | General |
| Category: Inflammation | ||||||
| 12/12/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $31.37 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $0.36 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $42.96 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Sandoz Inc. | HYRIMOZ (Biological) | Food and Beverage | In-kind items and services | $28.18 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $10.91 | General |
| Category: Immunology | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $128.00 | General |
| Category: Inflammation | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | Eli Lilly and Company | $467.57 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company | $320.45 | 2 |
| A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | Gilead Sciences, Inc. | $84.20 | 1 |
| A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arteritis | GlaxoSmithKline, LLC. | $79.36 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 1,308 | 214,158 | $3.3M | $1.7M |
| 2022 | 23 | 1,316 | 208,794 | $2.9M | $1.6M |
| 2021 | 28 | 1,577 | 136,326 | $2.6M | $1.6M |
| 2020 | 28 | 1,264 | 110,531 | $2.4M | $1.6M |
Total Patients
5,465
Total Services
669,809
Medicare Billing
$6.5M
Procedure Codes
101
All Medicare Procedures & Services
101 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 25 | 122,200 | $881,920 | $571,969 | 64.9% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 21 | 12,250 | $750,050 | $406,551 | 54.2% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 15 | 54,800 | $548,000 | $214,069 | 39.1% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 22 | 16,850 | $505,500 | $175,953 | 34.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 52 | 5,340 | $140,460 | $95,106 | 67.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 112 | 608 | $152,000 | $64,446 | 42.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 340 | 629 | $110,075 | $60,254 | 54.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 199 | 275 | $37,125 | $16,072 | 43.3% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 65 | 247 | $37,050 | $14,590 | 39.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 117 | 117 | $29,250 | $14,300 | 48.9% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 41 | 93 | $17,325 | $4,900 | 28.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 35 | 37 | $8,695 | $4,507 | 51.8% |
| 73120 | X-ray of hand, 2 views | Office | 2023 | 88 | 176 | $11,440 | $4,402 | 38.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 22 | 22 | $6,600 | $3,434 | 52.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 13 | 100 | $5,500 | $2,307 | 41.9% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 32 | 165 | $16,500 | $1,051 | 6.4% |
| 73560 | X-ray of knee, 1-2 views | Office | 2023 | 18 | 28 | $1,820 | $789.04 | 43.4% |
| 73620 | X-ray of foot, 2 views | Office | 2023 | 14 | 28 | $1,540 | $652.96 | 42.4% |
| 20600 | Aspiration and/or injection of fluid from small joint | Office | 2023 | 12 | 12 | $1,495 | $508.69 | 34.0% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 19 | 21 | $472.50 | $193.14 | 40.9% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 17 | 19 | $285.00 | $114.33 | 40.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 29 | 141 | $1,128 | $103.73 | 9.2% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2022 | 27 | 116,921 | $702,080 | $537,651 | 76.6% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 19 | 10,625 | $637,500 | $367,466 | 57.6% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 29 | 21,100 | $633,000 | $248,215 | 39.2% |
About Dr. Andrew Sulich, MD
Dr. Andrew Sulich, MD is a Rheumatology healthcare provider based in Saint Clair Shores, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508946385.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Sulich, MD has received a total of $2.2M in payments from pharmaceutical and medical device companies, with $253,081 received in 2024. These payments were reported across 4,373 transactions from 59 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.5M).
As a Medicare-enrolled provider, Sulich has provided services to 5,465 Medicare beneficiaries, totaling 669,809 services with total Medicare billing of $6.5M. Data is available for 4 years (2020–2023), covering 101 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Saint Clair Shores, MI
- Active Since 10/16/2006
- Last Updated 11/24/2020
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1508946385
Products in Payments
- Otezla (Drug) $633,256
- SAPHNELO (Biological) $299,161
- COSENTYX (Biological) $180,097
- Cimzia (Drug) $140,593
- TALTZ (Drug) $134,107
- Actemra (Biological) $122,257
- BENLYSTA (Biological) $101,877
- RINVOQ (Biological) $65,792
- KEVZARA (Biological) $61,281
- OLUMIANT (Drug) $44,438
- KEVZARA SARILUMAB INJECTION (Biological) $40,172
- LUPKYNIS (Drug) $35,046
- PURIFIED CORTROPHIN GEL (Drug) $33,447
- Otezla (Biological) $24,075
- Bimzelx (Biological) $23,039
- SKYRIZI (Biological) $19,586
- Rituxan (Biological) $19,314
- COSENTYX (Drug) $15,891
- TREMFYA (Drug) $12,142
- KEVZARA (Drug) $9,849
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.